Saba Shaikh, MD, talks with Sonia Pernas, MD, PhD, about the results of the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib combined with fulvestrant demonstrated promising efficacy in ER+/HER2- locally advanced or metastatic breast cancer patients previously treated using an aromatase inhibitor with a CDK4/6 inhibitor.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results of the Phase II SUMIT-BC Trial
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share: